Abstract
We detected a significant excess risk for CHEK2*1100delC mutation carriers to develop a contralateral breast tumor, OR = 6.5 (95% CI 1.5–28.8, p = 0.005). The highest percentage of mutation carriers was detected among those bilateral breast cancer patients who had received radiation treatment for their first breast tumor. These results warrant prolonged medical surveillance and may indicate a clinically important interaction between CHEK2 heterozygosity and radiation in the development of contralateral breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L et al.: A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749–1753, 1995
Matsuoka S, Huang M, Elledge SJ: Linkage of ATM to Cell Cycle regulation by the Chk2 protein kinase. Science 282: 1893–1897, 1998
Canman CE, Lim DS, Cimprich KA, Taya Y, Sakaguchi K, Appella E et al.: Activation of the ATM kinase by ionizing radiation an phosphorylation of p53. Science 11: 1677–1679, 1998
Bell DW, Varley J, Szydlo TE, Kang DH, Doke CRW: Heterozygous germline hCHK2 mutations in Li-Fraumeni syndrome. Science 286: 2528–2531, 1999
Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O et al.: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71: 432–438, 2002
Offit K, Pierce H, Kirchhoff T, Kolachana P, Rapaport B, Gregersen P et al.: Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 4: 1, 2003
Sodha N, Bullock S, Taylor R, Mitchell G, Guertl-Lackner B, Williams RD et al.: CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br J Cancer 87: 1445–1448, 2002
Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R et al.: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31: 55–59, 2002
Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG et al.: Variants in CHEK2 Other than 1100delC Do Not Make a Major Contribution to Breast Cancer Susceptibility. Am J Hum Genet 72: 1023–1028, 2003
Adami HO, Bergstrom R, Hansen J: Age at first primary as a determinant of the incidence of bilateral breast cancer: Cumulative and relative risks in a population-based case-control study. Cancer 55: 643, 1985
Boice Jr JD, Harvey EB, Blettner M, Stovall M, Flannarry JT: Cancer in the contralateral breast after radiotherapy for breast cancer. N Eng J Med 326: 1357–1358, 1992
Boice Jr JD, Storm HH, Curtis RE, OM Jensen, Kleinerman RA, Jensen HS et al.: Introduction to the study of multiple primary cancers. Natl Cancer Inst Monogr 68: 3, 1985
Fraass BA, Robertson PL, Lichter AS: Dose to the contralateral breast due to primary breast irradiation. Int J Radiat Oncol Biol Phys 11: 485, 1985
Tercilla O, Krasin F, Lawn-Tsao L: Comparison of contralateral breast doses from beam block and isocentric treatment techniques for patient treated with primary breast irradiation with 60Co. Int J Radiat Oncol Biol Phys 17: 205, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Broeks, A., de Witte, L., Nooijen, A. et al. Excess Risk for Contralateral Breast Cancer in CHEK2*1100delC Germline Mutation Carriers. Breast Cancer Res Treat 83, 91–93 (2004). https://doi.org/10.1023/B:BREA.0000010697.49896.03
Issue Date:
DOI: https://doi.org/10.1023/B:BREA.0000010697.49896.03